drugset / Trial / NCT00327808

Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma

NCT00327808

Phase 2 Completed 27 enrolled Syntara
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators will look at TPI-1020 safety and tolerability in mild to moderate asthmatic smoker subjects.

Timeline

Start
2006-05
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 400 ug Inhaled
Subject TPI 1020 Small molecule 600 ug Inhaled

Indications